Four-Fold Increase in Direct Costs of Stroke Survivors With Spasticity Compared With Stroke Survivors Without Spasticity: The First Year After the Event

Background and Purpose— The prevalence of spasticity after first-ever stroke is approximately 20%, but there are no health economic studies on costs associated with spasticity after stroke. The objective of our study was to estimate direct costs of stroke with spasticity for patients surviving up to 1 year after the stroke event in comparison to costs of stroke without spasticity. Methods— A representative sample of patients with first-ever stroke hospitalized at Uppsala University Hospital was eligible for our cross-sectional survey. All direct costs during 1 year were identified for each patient, including costs for hospitalization (acute and rehabilitation), primary health care, medication, and costs for municipality services. Swedish currency was converted to Purchasing Power Parities US dollar (PPP$). Results— Median age (interquartile range) was 73 years (18), and the proportion of women was 48%. The majority of the direct costs (78%) was associated with hospitalization, whereas 20% was associated with municipality services during 1 year after a first-ever stroke. Only 1% of all direct costs were related to primary health care and 1% to medication. The level of costs for patients with stroke was correlated with the presence of spasticity as measured with the modified Ashworth scale (rs=0.524) and with the degree of disability as measured with modified Rankin Scale (rs=0.624). The mean (median, interquartile range) direct cost for stroke patients with spasticity was PPP$ 84 195 (72 116, 53 707) compared with PPP$ 21 842 (12 385, 17 484) for patients with stroke without spasticity (P<0.001). Conclusions— Direct costs for 12-month stroke survivors are 4 times higher than direct costs for patients with stroke without spasticity during the first year after the event.

[1]  Imre Horváth,et al.  2 – Critical review of the literature , 1984 .

[2]  J. R. Greenwood Handbook of Neurological Rehabilitation , 2003 .

[3]  H. Rodgers,et al.  Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A , 2008, Trials.

[4]  K. Aho,et al.  Cerebrovascular disease in the community: results of a WHO collaborative study. , 1980, Bulletin of the World Health Organization.

[5]  Jeroen N. Struijs,et al.  International Comparison of Stroke Cost Studies , 2004, Stroke.

[6]  A. P. Moore,et al.  Management of spasticity in adults: practical application of botulinum toxin , 2006, European journal of neurology.

[7]  G. Cassel,et al.  Abnormal Deviations in International Exchanges , 1918 .

[8]  Jean-Michel Gracies,et al.  Pathophysiology of spastic paresis. I: Paresis and soft tissue changes , 2005, Muscle & nerve.

[9]  M. Leathley,et al.  Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. , 1999, Archives of physical medicine and rehabilitation.

[10]  L. Ada,et al.  Physiotherapy management of spasticity , 2001 .

[11]  AD Pandyan,et al.  Spasticity: Clinical perceptions, neurological realities and meaningful measurement , 2005, Disability and rehabilitation.

[12]  Garth R. Johnson,et al.  Upper Motor Neurone Syndrome and Spasticity: Clinical Management and Neurophysiology , 2008 .

[13]  M Barnes,et al.  BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. , 2010, Health technology assessment.

[14]  S. Gillard,et al.  Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. , 2005, Journal of rehabilitation medicine.

[15]  M. Leathley,et al.  Prevalence of spasticity post stroke , 2002, Clinical rehabilitation.

[16]  R. Young,et al.  Pathophysiology of spastic paresis , 1990 .

[17]  J. W. Archer,et al.  The Estimated Cost of Managing Focal Spasticity: A Physician Practice Patterns Survey , 2001, Neurorehabilitation and neural repair.

[18]  B. Stegmayr,et al.  Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. , 1992, Neuroepidemiology.

[19]  Bart Nooteboom,et al.  An International Comparison , 2000 .

[20]  Trends in Stroke Incidence and 10-Year Survival in Söderhamn, Sweden, 1975-2001 , 2003 .

[21]  B. Norrving,et al.  Stroke Incidence and Survival in the Beginning of the 21st Century in Southern Sweden: Comparisons With the Late 20th Century and Projections Into the Future , 2008, Stroke.

[22]  F. Molteni,et al.  Use of botulinum toxin type A in management of adult spasticity--a European consensus statement. , 2004, Journal of rehabilitation medicine.

[23]  L. Widén Holmqvist,et al.  Spasticity and Its Association with Functioning and Health-Related Quality of Life 18 Months after Stroke , 2006, Cerebrovascular Diseases.

[24]  James Thomas,et al.  International price comparisons based on purchasing power parity , 1999 .

[25]  BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM , 2000 .

[26]  P. Rothwell,et al.  Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature , 2009, Stroke.

[27]  J. Gracies,et al.  Pathophysiology of spastic paresis. II: Emergence of muscle overactivity , 2005, Muscle & nerve.

[28]  T. Mulder,et al.  Handbook of neurological rehabilitation , 2003 .

[29]  A. Térent A prospective epidemiological survey of cerebrovascular disease in a Swedish community. , 1979, Upsala journal of medical sciences.

[30]  J. Borg,et al.  Prevalence of disabling spasticity 1 year after first‐ever stroke , 2008, European journal of neurology.

[31]  D. Wade Upper motor neurone syndrome and spasticity. Clinical management and neurophysiology , 2001 .

[32]  A V Milholland,et al.  Medical assessment by a Delphi group opinion technic. , 1973, The New England journal of medicine.

[33]  A. Térent Increasing incidence of stroke among Swedish women. , 1988, Stroke.

[34]  A. Jahangir,et al.  Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. , 2007, The Medical journal of Malaysia.

[35]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[36]  M. V. von Arbin,et al.  Spasticity After Stroke: Its Occurrence and Association With Motor Impairments and Activity Limitations , 2003, Stroke.